Blood groups and Rhesus status as potential predictors of outcomes in patients with cardiac resynchronisation therapy.
Blood groups
Cardiac resynchronisation therapy
Heart failure
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
10 Apr 2024
10 Apr 2024
Historique:
received:
22
10
2023
accepted:
02
04
2024
medline:
11
4
2024
pubmed:
11
4
2024
entrez:
10
4
2024
Statut:
epublish
Résumé
Cardiac resynchronisation therapy (CRT) improves prognosis in patients with heart failure (HF) however the role of ABO blood groups and Rhesus factor are poorly understood. We hypothesise that blood groups may influence clinical and survival outcomes in HF patients undergoing CRT. A total of 499 patients with HF who fulfilled the criteria for CRT implantation were included. Primary outcome of all-cause mortality and/or heart transplant/left ventricular assist device was assessed over a median follow-up of 4.6 years (IQR 2.3-7.5). Online repositories were searched to provide biological context to the identified associations. Patients were divided into blood (O, A, B, and AB) and Rhesus factor (Rh-positive and Rh-negative) groups. Mean patient age was 66.4 ± 12.8 years with a left ventricular ejection fraction of 29 ± 11%. There were no baseline differences in age, gender, and cardioprotective medication. In a Cox proportional hazard multivariate model, only Rh-negative blood group was associated with a significant survival benefit (HR 0.68 [0.47-0.98], p = 0.040). No association was observed for the ABO blood group (HR 0.97 [0.76-1.23], p = 0.778). No significant interaction was observed with prevention, disease aetiology, and presence of defibrillator. Rhesus-related genes were associated with erythrocyte and platelet function, and cholesterol and glycated haemoglobin levels. Four drugs under development targeting RHD were identified (Rozrolimupab, Roledumab, Atorolimumab, and Morolimumab). Rhesus blood type was associated with better survival in HF patients with CRT. Further research into Rhesus-associated pathways and related drugs, namely whether there is a cardiac signal, is required.
Identifiants
pubmed: 38600217
doi: 10.1038/s41598-024-58747-8
pii: 10.1038/s41598-024-58747-8
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
8371Subventions
Organisme : UCL BHF Research Accelerator
ID : AA/18/6/34223
Organisme : NIHR grant
ID : NIHR129463
Organisme : UKRI grant
ID : Horizon Europe ARISTOTELES project
Informations de copyright
© 2024. The Author(s).
Références
Bragazzi, N. L. et al. Burden of heart failure and underlying causes in 195 countries and territories from 1990 to 2017. Eur. J. Prev. Cardiol. 28(15), 1682–1690 (2021).
doi: 10.1093/eurjpc/zwaa147
pubmed: 33571994
Tsao, C. W. et al. Heart disease and stroke statistics-2022 update: A report from the American heart association. Circulation. 145(8), e153–e639 (2022).
doi: 10.1161/CIR.0000000000001052
pubmed: 35078371
Bozkurt, B. et al. 2021 ACC/AHA key data elements and definitions for heart failure: A report of the American College of Cardiology/American Heart Association Task force on clinical data standards (writing committee to develop clinical data standards for heart failure). Circ. Cardiovasc. Qual. Outcomes. 14(4), e000102 (2021).
doi: 10.1161/HCQ.0000000000000102
pubmed: 33755495
pmcid: 8059763
Daubert, C., Behar, N., Martins, R. P., Mabo, P. & Leclercq, C. Avoiding non-responders to cardiac resynchronization therapy: A practical guide. Eur. Heart J. 38(19), 1463–1472 (2017).
pubmed: 27371720
Schiavone, M. et al. Cardiac resynchronization therapy: Present and future. Eur. Heart J. Suppl. 25(Suppl C), C227–C233 (2023).
doi: 10.1093/eurheartjsupp/suad046
pubmed: 37125274
pmcid: 10132566
Providencia, R. et al. Usefulness of a clinical risk score to predict the response to cardiac resynchronization therapy. Int. J. Cardiol. 260, 82–87 (2018).
doi: 10.1016/j.ijcard.2018.02.012
pubmed: 29622458
Papageorgiou, N. et al. Does presence of left ventricular contractile reserve improve response to cardiac resynchronization therapy? An updated meta-analysis. Int. J. Cardiol. 252, 224–228 (2018).
doi: 10.1016/j.ijcard.2017.09.034
pubmed: 29249433
Ioannou, A. et al. Impact of an age-adjusted co-morbidity index on survival of patients with heart failure implanted with cardiac resynchronization therapy devices. Am. J. Cardiol. 120(7), 1158–1165 (2017).
doi: 10.1016/j.amjcard.2017.06.056
pubmed: 28784235
Papageorgiou, N. et al. Full blood count as potential predictor of outcomes in patients undergoing cardiac resynchronization therapy. Sci. Rep. 9(1), 13016 (2019).
doi: 10.1038/s41598-019-49659-z
pubmed: 31506584
pmcid: 6736835
Roselli, C., Rienstra, M. & Ellinor, P. T. Genetics of atrial fibrillation in 2020: GWAS, genome sequencing, polygenic risk, and beyond. Circ. Res. 127(1), 21–33 (2020).
doi: 10.1161/CIRCRESAHA.120.316575
pubmed: 32716721
pmcid: 7388073
Shah, S. et al. Genome-wide association and Mendelian randomisation analysis provide insights into the pathogenesis of heart failure. Nat. Commun. 11(1), 163 (2020).
doi: 10.1038/s41467-019-13690-5
pubmed: 31919418
pmcid: 6952380
Groot, H. E. et al. Genetically determined ABO blood group and its associations with health and disease. Arterioscler. Thromb. Vasc. Biol. 40(3), 830–838 (2020).
doi: 10.1161/ATVBAHA.119.313658
pubmed: 31969017
Chung, C. M. et al. A genome-wide association study identifies new loci for ACE activity: Potential implications for response to ACE inhibitor. Pharmacogenom. J. 10(6), 537–544 (2010).
doi: 10.1038/tpj.2009.70
Kiechl, S. et al. Association of variation at the ABO locus with circulating levels of soluble intercellular adhesion molecule-1, soluble P-selectin, and soluble E-selectin: A meta-analysis. Circ. Cardiovasc. Genet. 4(6), 681–686 (2011).
doi: 10.1161/CIRCGENETICS.111.960682
pubmed: 22010135
pmcid: 3278232
Wu, O., Bayoumi, N., Vickers, M. A. & Clark, P. ABO(H) blood groups and vascular disease: A systematic review and meta-analysis. J. Thromb. Haemost. 6(1), 62–69 (2008).
doi: 10.1111/j.1538-7836.2007.02818.x
pubmed: 17973651
Teslovich, T. M. et al. Biological, clinical and population relevance of 95 loci for blood lipids. Nature. 466(7307), 707–713 (2010).
doi: 10.1038/nature09270
pubmed: 20686565
pmcid: 3039276
Hartiala, J. A. et al. Genome-wide analysis identifies novel susceptibility loci for myocardial infarction. Eur. Heart J. 42(9), 919–933 (2021).
doi: 10.1093/eurheartj/ehaa1040
pubmed: 33532862
pmcid: 7936531
Wang, Q. et al. Premature myocardial infarction novel susceptibility locus on chromosome 1P34-36 identified by genomewide linkage analysis. Am. J. Hum. Genet. 74(2), 262–271 (2004).
doi: 10.1086/381560
pubmed: 14732905
pmcid: 1181924
Guo, Y. et al. Genome-wide linkage analysis of large multiple multigenerational families identifies novel genetic loci for coronary artery disease. Sci. Rep. 7(1), 5472 (2017).
doi: 10.1038/s41598-017-05381-2
pubmed: 28710368
pmcid: 5511258
van der Harst, P. & Verweij, N. Identification of 64 novel genetic loci provides an expanded view on the genetic architecture of coronary artery disease. Circ. Res. 122(3), 433–443 (2018).
doi: 10.1161/CIRCRESAHA.117.312086
pubmed: 29212778
pmcid: 5805277
(NICOR) NIfCOR. National Clinical Audit on Device Implantation. (2024).
Ponikowski, P. et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur. Heart J. 37(27), 2129–2200 (2016).
doi: 10.1093/eurheartj/ehw128
pubmed: 27206819
Dahlen, T., Clements, M., Zhao, J., Olsson, M. L. & Edgren, G. An agnostic study of associations between ABO and RhD blood group and phenome-wide disease risk. Elife. 10, 1–10 (2021).
doi: 10.7554/eLife.65658
Gotsman, I., Keren, A., Zwas, D. R., Lotan, C. & Admon, D. Clinical impact of ABO and Rhesus D blood type groups in patients with chronic heart failure. Am. J. Cardiol. 122(3), 413–419 (2018).
doi: 10.1016/j.amjcard.2018.04.018
pubmed: 29958715
Huang, C., Chen, Y., Reid, M. & Ghosh, S. Genetic recombination at the human RH locus: A family study of the red-cell Evans phenotype reveals a transfer of exons 2–6 from the RHD to the RHCE gene. Am. J. Hum. Genet. 59(4), 825–833 (1996).
pubmed: 8808597
pmcid: 1914783
NHGRI-EBI Catalog of human genome-wide association studies (GWAS-Catalog). https://www.ebi.ac.uk/gwas/home . Accessed 15 Aug 2022.
Drug Gene Interaction Database (DGIdb). https://dgidb.org/ . Accessed 22 Aug 2022.
Open Targets. https://www.opentargets.org/ . Accessed 22 Aug 2022.
ChEMBL. https://www.ebi.ac.uk/chembl/ . Accessed 22 Aug 2022.
Cherif-Zahar, B. et al. Localization of the human Rh blood group gene structure to chromosome region 1p34.3–1p36.1 by in situ hybridization. Hum. Genet. 86(4), 398–400 (1991).
doi: 10.1007/BF00201843
pubmed: 1900257
Vaidya, G. N. et al. Effect of blood group on heart transplant waitlist mortality in the ventricular assist device era. ASAIO J. 66(7), 774–779 (2020).
doi: 10.1097/MAT.0000000000001080
pubmed: 31577625
Baldwin, C., Pandey, J. & Olarewaju, O. Haemolytic Anaemia (StatPearls, 2022).
Rinkuniene, D. et al. Predictors of positive response to cardiac resynchronization therapy. BMC Cardiovasc. Disord. 14, 55 (2014).
doi: 10.1186/1471-2261-14-55
pubmed: 24779476
pmcid: 4016658
Diaz-Infante, E. et al. Predictors of lack of response to resynchronization therapy. Am. J. Cardiol. 95(12), 1436–1440 (2005).
doi: 10.1016/j.amjcard.2005.02.009
pubmed: 15950566
Di Tanna, G. L., Wirtz, H., Burrows, K. L. & Globe, G. Evaluating risk prediction models for adults with heart failure: A systematic literature review. PLoS ONE. 15(1), e0224135 (2020).
doi: 10.1371/journal.pone.0224135
pubmed: 31940350
pmcid: 6961879
Anderson, J. L. et al. Association of Rhesus factor blood type with risk of SARS-CoV-2 infection and COVID-19 severity. Br. J. Haematol. 197(5), 573–575 (2022).
doi: 10.1111/bjh.18086
pubmed: 35106763
Williamson, E. J. et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature. 584(7821), 430–436 (2020).
doi: 10.1038/s41586-020-2521-4
pubmed: 32640463
pmcid: 7611074
Strongman, H., Carreira, H., De Stavola, B. L., Bhaskaran, K. & Leon, D. A. Factors associated with excess all-cause mortality in the first wave of the COVID-19 pandemic in the UK: A time series analysis using the Clinical Practice Research Datalink. PLoS Med. 19(1), e1003870 (2022).
doi: 10.1371/journal.pmed.1003870
pubmed: 34990450
pmcid: 8735664
Ray, J. G., Schull, M. J., Vermeulen, M. J. & Park, A. L. Association between ABO and Rh blood groups and SARS-CoV-2 infection or severe COVID-19 illness: A population-based cohort study. Ann. Intern. Med. 174(3), 308–315 (2021).
doi: 10.7326/M20-4511
pubmed: 33226859
Zietz, M., Zucker, J. & Tatonetti, N. P. Associations between blood type and COVID-19 infection, intubation, and death. Nat. Commun. 11(1), 5761 (2020).
doi: 10.1038/s41467-020-19623-x
pubmed: 33188185
pmcid: 7666188
Cazeau, S. J., Daubert, J. C., Tavazzi, L., Frohlig, G. & Paul, V. Responders to cardiac resynchronization therapy with narrow or intermediate QRS complexes identified by simple echocardiographic indices of dyssynchrony: The DESIRE study. Eur. J. Heart Fail. 10(3), 273–280 (2008).
doi: 10.1016/j.ejheart.2008.02.007
pubmed: 18314381
Chung, E. S. et al. Results of the predictors of response to CRT (PROSPECT) trial. Circulation. 117(20), 2608–2616 (2008).
doi: 10.1161/CIRCULATIONAHA.107.743120
pubmed: 18458170
Ruschitzka, F. et al. Cardiac-resynchronization therapy in heart failure with a narrow QRS complex. N. Engl. J. Med. 369(15), 1395–1405 (2013).
doi: 10.1056/NEJMoa1306687
pubmed: 23998714